Attached files
file | filename |
---|---|
8-K - FORM 8-K - ANAVEX LIFE SCIENCES CORP. | form8k.htm |
EX-10.1 - AMENDED STOCK OPTION AGREEMENT DATED SEPTEMBER 16, 2011 - ANAVEX LIFE SCIENCES CORP. | exhibit10-1.htm |
Anavex announces director resignation
Hoboken, NJ September 16, 2011 -- Anavex Life Sciences Corp. (Anavex) reports that Dr. Cameron Durrant has resigned as Director and Executive Chairman of the Board effective immediately. Anavexs Board of Directors would like to thank Dr. Durrant for his contributions to the company and wish him well in his future endeavors.
About Anavex Life Sciences Corp.
Anavex Life Sciences
Corp. (www.anavex.com) is a specialty pharmaceutical company engaged in the
discovery and development of novel drug candidates for the treatment of
neurological diseases and cancer. The Anavex proprietary SIGMACEPTOR Discovery
Platform involves the rational design of drug compounds targeted to specific
receptors involved in the modulation of multiple cellular biochemical signaling
pathways.
The SIGMACEPTOR-N program involves the development of novel drug candidates that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy, depression, pain). The company's lead drug candidates exhibit high affinity for sigma receptors, which have been extensively documented as potentially valuable drug targets and have demonstrated anti-amnesic and neuroprotective properties. A portfolio of back-up compounds to ANAVEX 2-73 are also in development.
Anavex is a publicly traded company under the symbol AVXL.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase, our ability to retain key employees and our ability to finance development or satisfy the rigorous regulatory requirements for new drugs. Competitors may develop better or cheaper alternatives to our products. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information |
Anavex Life Sciences Corp. |
Research & Business Development |
Email: info@anavex.com |
Shareholder & Media Relations |
Toll-free: 1-866-505-2895 |
Outside North America: +1 (416) 489-0092 |
Email: ir@anavex.com |
www.anavex.com |